Clearmind Medicine Converts $1.75M in Notes at $0.60/Share, Causing Significant Dilution

summarizeSummary

Clearmind Medicine converted $1.75 million in promissory notes into common shares at a discounted price of $0.60 per share, leading to significant dilution for existing shareholders.

check_boxKey Events

• Convertible Notes Converted

  $1.75 million in convertible promissory notes were converted into common shares.

• Discounted Conversion Price

  The conversion occurred at an agreed price of $0.60 per common share, a discount to the current market price of $0.7682.

• Significant Share Issuance

  Approximately 2.92 million new common shares were issued as a result of the conversion.

• Floor Price Amendment

  The floor price for future conversions under the existing securities purchase agreements was amended to $0.60 per common share.

auto_awesomeAnalysis

This filing details the conversion of $1.75 million in convertible promissory notes, previously announced on April 14, 2026, into common shares. The conversion occurred at a price of $0.60 per share, representing a substantial discount to the current market price of $0.7682. This conversion results in the issuance of approximately 2.92 million new shares, significantly diluting existing shareholders. The amendment of the floor price to $0.60 per share further solidifies this lower valuation for future conversions under the existing $10 million program.